Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | TNO155 |
Trade Name | |
Synonyms | TNO-155|TNO 155 |
Drug Descriptions |
TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent cell growth (NCI Drug Dictionary). |
DrugClasses | SHP2 Inhibitor 19 |
CAS Registry Number | NA |
NCIT ID | C139559 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Adagrasib + TNO155 | Adagrasib TNO155 | 0 | 1 |
Dabrafenib + LTT462 + TNO155 | Dabrafenib LTT462 TNO155 | 0 | 1 |
Dabrafenib + TNO155 + Trametinib | Dabrafenib TNO155 Trametinib | 0 | 1 |
JDQ443 + Spartalizumab + TNO155 | JDQ443 Spartalizumab TNO155 | 0 | 0 |
JDQ443 + Tislelizumab + TNO155 | JDQ443 TNO155 Tislelizumab | 0 | 1 |
JDQ443 + TNO155 | JDQ443 TNO155 | 0 | 1 |
Ribociclib + TNO155 | Ribociclib TNO155 | 0 | 1 |
Sotorasib + TNO155 | Sotorasib TNO155 | 0 | 1 |
Spartalizumab + TNO155 | Spartalizumab TNO155 | 0 | 1 |
TNO155 | TNO155 | 2 | 1 |